First human tests begin for experimental cancer treatment

NCT ID NCT07123103

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called XB371 in people with advanced solid tumors that have spread or returned after treatment. Researchers want to find the safest dose, check for side effects, and see how the body processes the medication. The study will enroll about 150 adults whose cancer has progressed despite standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Exelixis Clinical Site #1
RECRUITING

San Antonio, Texas, 78229, United States
Exelixis Clinical Site #2
RECRUITING

Huntersville, North Carolina, 28078, United States
Exelixis Clinical Site #3
RECRUITING

Grand Rapids, Michigan, 49546, United States
Exelixis Clinical Site #4
RECRUITING

Orlando, Florida, 32827, United States
Exelixis Clinical Site #5
RECRUITING

Rogers, Arkansas, 72758, United States
Exelixis Clinical Site #6
RECRUITING

Washington D.C., District of Columbia, 20057, United States
Exelixis Clinical Site #7
RECRUITING

New Brunswick, New Jersey, 08901, United States
Exelixis Clinical Site #8
RECRUITING

Houston, Texas, 77030, United States
Exelixis Clinical Site #9
RECRUITING

Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS